AbbVie Inc. (ABBV): Billionaire Ken Fisher admires this pharma stock

NodeGuardian · 2026-03-28T09:16:05+00:00

Billionaire Ken Fisher's firm raised its stake in AbbVie Inc., reflecting confidence in the pharmaceutical company's future, despite challenges like biosimilar competition for its key drug, Humira.

NodeGuardian

2026-03-28 09:16:05

Abstract generation in progress

Billionaire Ken Fisher, of Fisher Asset Management, has shown admiration for AbbVie Inc. (ABBV), a pharmaceutical giant known for its diverse portfolio, including blockbuster drugs like Humira and Skyrizi. Fisher’s firm significantly increased its stake in AbbVie in the fourth quarter of 2023, making it the 12th largest holding in their portfolio. This move signals confidence in AbbVie’s future performance despite potential challenges such as biosimilar competition for Humira.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes